FINWIRES · TerminalLIVE
FINWIRES

$PTGX

11 stories mentioning PTGXUpdated 11d ago

Every FINWIRES story that references PTGX, newest first.

What are analysts saying about PTGX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on PTGX?

Insider Trading

Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing

Dinesh V Patel, Director, President and Chief Executive Officer, on September 08, 2026, sold 125,000 shares in Protagonist Therapeutics (PTGX) for $18,240,568. Following the Form 4 filing with the SEC, Patel has control over a total of 522,968 common shares of the company, with 522,968 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/xslF345X05/tm2625158-1_4seq1.xml

$PTGX
Wire

Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

Protagonist Therapeutics (PTGX) could have attractive commercial potential for Mimrylo following the US Food and Drug Administration's approval for treating polycythemia vera, a rare blood cancer, Truist Securities said in a note Monday.Mimrylo label's lack of a black-box warning, fatigue improvement and self-administration could support patient adoption, Truist said.The brokerage also expects payer approval given Mimrylo's potential to reduce the recurring burden of phlebotomies, while noting the treatment can be added to patients' existing PV therapy.Truist also expects Mimrylo to have three to four years of "uncontested commercialization."Truist maintained a buy rating with a $170 price target.Price: $144.97, Change: $+0.64, Percent Change: +0.44%

$PTGX
Wire

Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept

Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $159.36, according to analysts polled by FactSet.Price: $144.97, Change: $+0.64, Percent Change: +0.44%

$PTGX
Wire

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

Protagonist Therapeutics' (PTGX) future growth will hinge more on its wholly owned programs than on its newly approved partner therapy, with the company's first clinical readouts from its proprietary pipeline expected in H1 2027. Wedbush Securities said Monday in a report.Wedbush highlighted PN-8047, an oral version of rusfertide, a treatment recently approved for polycythemia vera and commercialized by Takeda Pharmaceutical (TAK). PN-8047 appears similarly potent and may move into a phase 2 study in 2027 if early safety and iron-lowering data are positive, the report said.Protagonist's cash position is strengthened by payments tied to rusfertide's regulatory approval, including a $200 million opt-out fee and a $75 million milestone, along with similar payments from Johnson & Johnson (JNJ) for icotyde, an oral anti-inflammatory drug being developed for psoriasis and other immune conditions, the report said.Wedbush maintained its outperform rating on Protagonist stock with a $173 price target.Price: $144.35, Change: $+0.02, Percent Change: +0.01%

$JNJ$PTGX$TAK
Insider Trading

Protagonist Therapeutics Insider Sold Shares Worth $14,890,799, According to a Recent SEC Filing

Dinesh V Patel, Director, President and Chief Executive Officer, on August 10, 2026, sold 100,000 shares in Protagonist Therapeutics (PTGX) for $14,890,799. Following the Form 4 filing with the SEC, Patel has control over a total of 523,478 common shares of the company, with 523,478 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1377121/000110465926095111/xslF345X05/tm2622954-1_4seq1.xml

$PTGX
Wire

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a "more convenient dosing profile," supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics' (PTGX) rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, the report said.Morgan Stanley reiterated its overweight rating on Silence Therapeutics and raised its price target to $32 from $25.Price: $15.14, Change: $-0.29, Percent Change: -1.88%

$PTGX$SLN
Research

Goldman Sachs Upgrades Protagonist Therapeutics to Buy From Neutral, Adjusts PT to $186 From $110

Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $159.36, according to analysts polled by FactSet.

$PTGX
Insider Trading

Protagonist Therapeutics Insider Sold Shares Worth $1,061,460, According to a Recent SEC Filing

William D. Waddill, Director, on June 23, 2026, sold 9,000 shares in Protagonist Therapeutics (PTGX) for $1,061,460. Following the Form 4 filing with the SEC, Waddill has control over a total of 7,825 common shares of the company, with 7,825 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/xslF345X05/tm2618679-1_4seq1.xml

$PTGX
Insider Trading

Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing

Dinesh V Patel Ph.D., Director, President and Chief Executive Officer, on May 12, 2026, sold 75,000 shares in Protagonist Therapeutics (PTGX) for $7,509,000. Following the Form 4 filing with the SEC, Patel has control over a total of 523,478 common shares of the company, with 523,478 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1377121/000110465926059591/xslF345X05/tm2614444-1_4seq1.xml

$PTGX
Wire

Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating

Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $116.31, according to analysts polled by FactSet.Price: $104.30, Change: $+5.09, Percent Change: +5.13%

$PTGX
Wire

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

Protagonist Therapeutics (PTGX) exercised its right to opt out of the 50/50 US profit and loss sharing arrangement under its global license and collaboration agreement with Takeda Pharmaceutical (TAK) for rusfertide, Protagonist Therapeutics said Tuesday.As a result, Protagonist Therapeutics will be eligible to receive up to $400 million in opt-out payments.The company will also be entitled to a $75 million milestone payment upon rusfertide's approval in the US and up to $975 million in other milestone payments and tiered royalties on net sales, according to the statement.Takeda Pharmaceutical now holds exclusive development and commercialization rights to rusfertide in the US.Rusfertide is under FDA Priority Review in the US for the treatment of adult patients with polycythemia vera, Protagonist Therapeutics said.Price: $99.31, Change: $+0.84, Percent Change: +0.85%

$PTGX$TAK

Track with the FINWIRES app suite

FolioX
FolioX
Track PTGX in your portfolio
WheelAI
WheelAI
Analyze PTGX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on PTGX